Periodic Glucose Sensor Monitoring for Adults with Type 2 Diabetes
Tests periodic continuous glucose monitoring versus finger-prick checks in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Periodic Continuous Glucose Monitoring in Patients With Type 2 Diabetes
Key facts
- Where
- Stockholm, SwedenSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05633628, who can take part
Where in Sweden
- Sophiahemmet UniversityStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sophiahemmet University
- Trial code
- NCT05633628
- Record updated
- 29 April 2026
- Original description
The aim of this randomised controlled trial is to investigate the effectiveness of periodic CGM (continuous glucose monitoring) to support a person-centered approach versus self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes on glucose control and patient reported outcomes.Read full original descriptionShow less
Periodic Continuous Glucose Monitoring to Support a Person-centered Approach During Diabetes Consultations in Patients With Type 2 Diabetes- A Randomised Controlled Study
The aim of this randomised controlled trial is to investigate the effectiveness of periodic CGM (continuous glucose monitoring) to support a person-centered approach versus self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes on glucose control and patient reported outcomes.
Inclusion: Adults aged 18-80 years; Type 2 diabetes with a duration of > 6 months; HbA1c 45-70 mmol/mol; Have a smartphone; Experience of self-monitoring of blood glucose prior to the study start.
Exclusion: Planned or currently using weight reduction medications, programs, or surgery; Active malignancy or under investigation for malignancy; Severe visual impairment; Eating disorders; Renal disease with estimated glomerular filtration rate (eGFR) <45 mL/ min/1.73 m2; Severe skin allergy that inhibits the use of a continuous glucose monitoring device; Prandial insulin; Pregnancy or planning pregnancy during the study; Breastfeeding; Glucocorticoids (systemic); Cognitively or psychologically unable to participate and read instructions; Enrolled in other clinical trials.